NewAmsterdam Pharma Company NAMS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.04M+9,400% | $32K-90.8% | $348K-98.2% | $19.15M+543% | $2.98M-76.7% | ||
| $38.01M-1.5% | $38.59M+24.6% | $30.97M+12.6% | $27.52M-38.5% | $44.75M+28.2% | ||
| $23.45M-14.5% | $27.42M+11.8% | $24.52M-10.1% | $27.26M+0.4% | $27.15M+28.6% | ||
| $61.46M-6.9% | $66.01M+19.0% | $55.49M+1.3% | $54.78M-23.8% | $71.9M+28.4% | ||
| -$58.42M+11.5% | -$65.98M-19.7% | -$55.14M-54.7% | -$35.64M+48.3% | -$68.93M-59.4% | ||
| -1,921.7%+204,266pp | -206,187.5%-190,342pp | -15,845.7%-15,660pp | -186.1%+2,128pp | -2,314.5%-1,976pp | ||
| -$1.61M— | $0-100% | $218K-97.5% | $8.63M+101% | $4.29M+155% | ||
| -$48.44M+35.3% | -$74.92M-4.1% | -$72.01M-315% | -$17.36M+56.1% | -$39.53M+57.1% | ||
| —— | —— | —— | —— | —— | ||
| -$48.44M+35.3% | -$74.92M-4.1% | -$72.01M-315% | -$17.36M+56.1% | -$39.53M+57.1% | ||
| -1,593.5%+232,541pp | -234,134.4%-213,443pp | -20,691.1%-20,600pp | -90.7%+1,237pp | -1,327.3%-606pp | ||
| -$0.40+36.5% | -$0.63-3.3% | -$0.61-307% | -$0.15+55.9% | -$0.34+64.2% | ||
| -$58.36M+11.5% | -$65.92M-19.7% | -$55.08M-54.8% | -$35.59M+48.3% | -$68.87M-59.5% | ||
| -1,919.7%+204,083pp | -206,003.1%-190,176pp | -15,827.3%-15,641pp | -185.9%+2,127pp | -2,312.7%-1,975pp | ||
| -$58.42M+11.5% | -$65.98M-19.7% | -$55.14M-54.7% | -$35.64M+48.3% | -$68.93M-59.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's income statement data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.